Takeda completed the acquisition of Nimbus Lakshmi for $6bn.

Takeda, a pharmaceutical company, completed the acquisition of Nimbus Lakshmi, a wholly-owned subsidiary of Nimbus Therapeutics, a developer of small molecule compounds, for $6bn. “We are thrilled to reach this important milestone for what we believe is a best-in-class molecule in the new therapeutic class of oral, selective allosteric TYK2 inhibitors, which has the potential to address high unmet need for patients across a broad range of immune-mediated diseases. We look forward to continuing to design future breakthrough medicines, leveraging Nimbus’ unique approach at the intersection of computational chemistry and pharmaceutical sciences, and building on our track record of success.” Jeb Keiper, Nimbus CEO.